Tardive dyskinesia shows up in roughly 1 in 5 patients on long-term antipsychotics, but most PMHNPs only know how to spot the dramatic cases. By then the damage is done. This Deep Dive breaks down the 2026 screening playbook: how to actually run the AIMS exam inside a 30-minute med visit, who's truly high-risk (it isn't who you think), when to start a VMAT2 inhibitor like valbenazine or deutetrabenazine, and the prescribing red flags that mean it's time to slow down and call a colleague. We also cover the legal angle every new prescriber needs to understand — what informed consent for antipsychotics actually requires in 2026, and why "I told them about side effects" isn't enough. Based on the full guide at psychnpfellowship.com/tardive-dyskinesia-pmhnp-screening-playbook-2026/